{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:29:57Z","timestamp":1780734597066,"version":"3.54.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thoracic.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Surgery Clinics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.thorsurg.2020.08.005","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:25:45Z","timestamp":1599931545000},"page":"383-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["The Molecular Basis of Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"30","author":[{"given":"Benjamin","family":"Wadowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"De Rienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.thorsurg.2020.08.005_bib1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: a review","volume":"7","author":"Broeckx","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"12","key":"10.1016\/j.thorsurg.2020.08.005_bib2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-642-10862-4_5","article-title":"Pathohistological diagnosis and differential diagnosis","volume":"189","author":"Tischoff","year":"2011","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.005_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.athoracsur.2016.08.063","article-title":"Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma","volume":"103","author":"Vigneswaran","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.thorsurg.2020.08.005_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.thorsurg.2020.08.005_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.thorsurg.2020.08.005_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061603","article-title":"Heterogeneity in malignant pleural mesothelioma","volume":"19","author":"Oehl","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.thorsurg.2020.08.005_bib8","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib9","author":"Network"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib10","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review","author":"Khan","year":"2019","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"10.1016\/j.thorsurg.2020.08.005_bib11","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jtho.2019.03.030","volume":"14","author":"Gomez","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.thorsurg.2020.08.005_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant mesothelioma and its non-asbestos causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.thorsurg.2020.08.005_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00280-019-03878-3","article-title":"The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment","volume":"84","author":"Galani","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.thorsurg.2020.08.005_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajim.22985","article-title":"Quantitative relationships of exposure to chrysotile asbestos and mesothelioma mortality","volume":"62","author":"Loomis","year":"2019","journal-title":"Am J Ind Med"},{"issue":"11","key":"10.1016\/j.thorsurg.2020.08.005_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.21037\/atm.2017.06.60","article-title":"Diagnosis and prognosis-review of biomarkers for mesothelioma","volume":"5","author":"Sun","year":"2017","journal-title":"Ann Transl Med"},{"issue":"1\u20134","key":"10.1016\/j.thorsurg.2020.08.005_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10937404.2011.556051","article-title":"Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases","volume":"14","author":"Huang","year":"2011","journal-title":"J\u00a0Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3389\/fonc.2019.01293","article-title":"Epigenetic regulation of miRNA expression in malignant mesothelioma: miRNAs as biomarkers of early diagnosis and therapy","volume":"9","author":"Tomasetti","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.thorsurg.2020.08.005_bib18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00204-018-2179-y","article-title":"DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response","volume":"92","author":"Casalone","year":"2018","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.freeradbiomed.2017.12.008","article-title":"Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane","volume":"115","author":"Nuvoli","year":"2018","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"10.1016\/j.thorsurg.2020.08.005_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","article-title":"Advances in the biology of malignant pleural mesothelioma","volume":"37","author":"Zucali","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.thorsurg.2020.08.005_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/labinvest.3700109","article-title":"Asbestos-derived reactive oxygen species activate TGF-beta1","volume":"84","author":"Pociask","year":"2004","journal-title":"Lab Invest"},{"issue":"7","key":"10.1016\/j.thorsurg.2020.08.005_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/thx.54.7.638","article-title":"The molecular basis of asbestos induced lung injury","volume":"54","author":"Kamp","year":"1999","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.thorsurg.2020.08.005_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/15287394.2017.1416911","article-title":"A\u00a0genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma","volume":"81","author":"Crovella","year":"2018","journal-title":"J\u00a0Toxicol Environ Health A"},{"issue":"20","key":"10.1016\/j.thorsurg.2020.08.005_bib24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/15287394.2019.1694612","article-title":"Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes","volume":"82","author":"Celsi","year":"2019","journal-title":"J\u00a0Toxicol Environ Health A"},{"issue":"1","key":"10.1016\/j.thorsurg.2020.08.005_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.005_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","article-title":"Molecular changes in mesothelioma with an impact on prognosis and treatment","volume":"136","author":"Jean","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.thorsurg.2020.08.005_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.005_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/path.1128","article-title":"Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases","volume":"197","author":"Krismann","year":"2002","journal-title":"J\u00a0Pathol"},{"issue":"10","key":"10.1016\/j.thorsurg.2020.08.005_bib29","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"7","key":"10.1016\/j.thorsurg.2020.08.005_bib30","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"issue":"1\u20132","key":"10.1016\/j.thorsurg.2020.08.005_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000109618","article-title":"Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH","volume":"119","author":"Lindholm","year":"2007","journal-title":"Cytogenet Genome Res"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.005_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","article-title":"Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration","volume":"17","author":"Borczuk","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.thorsurg.2020.08.005_bib33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.lungcan.2007.06.015","article-title":"DNA methylation profile of 28 potential marker loci in malignant mesothelioma","volume":"58","author":"Tsou","year":"2007","journal-title":"Lung Cancer"},{"issue":"23","key":"10.1016\/j.thorsurg.2020.08.005_bib34","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.thorsurg.2020.08.005_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome","volume":"69","author":"Christensen","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.thorsurg.2020.08.005_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/path.4567","article-title":"Epigenetic down-regulation of integrin alpha7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma","volume":"237","author":"Laszlo","year":"2015","journal-title":"J\u00a0Pathol"},{"issue":"14","key":"10.1016\/j.thorsurg.2020.08.005_bib37","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/0008-5472.CAN-10-0190","article-title":"Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma","volume":"70","author":"Christensen","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the treatment of malignant pleural mesothelioma: past, present and future","volume":"10","author":"Reid","year":"2020","journal-title":"Front Oncol"},{"issue":"14 Supplement","key":"10.1016\/j.thorsurg.2020.08.005_bib39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/1538-7445.AM2016-112","article-title":"Abstract 112: genetic alterations in molecular tumor subgroups of malignant pleural mesothelioma","volume":"76","author":"Quetel","year":"2016","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.thorsurg.2020.08.005_bib40","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"issue":"15_suppl","key":"10.1016\/j.thorsurg.2020.08.005_bib41","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1200\/JCO.2018.36.15_suppl.8516","article-title":"The TCGA malignant pleural mesothelioma (MPM) project: VISTA expression and delineation of a novel clinical-molecular subtype of MPM","volume":"36","author":"Ladanyi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.005_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.thorsurg.2020.08.005_bib43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.thorsurg.2020.08.005_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/0008-5472.CAN-15-0751","article-title":"Gender-specific molecular and clinical features underlie malignant pleural mesothelioma","volume":"76","author":"De Rienzo","year":"2016","journal-title":"Cancer Res"},{"issue":"7659","key":"10.1016\/j.thorsurg.2020.08.005_bib45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca(2+) flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.thorsurg.2020.08.005_bib46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the management of malignant pleural mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.thorsurg.2020.08.005_bib47","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.thorsurg.2020.08.005_bib48","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.005_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ht7030020","article-title":"Genomics and epigenetics of malignant mesothelioma","volume":"7","author":"Sage","year":"2018","journal-title":"High Throughput"},{"issue":"5","key":"10.1016\/j.thorsurg.2020.08.005_bib50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/lmt.15.21","article-title":"Causes and pathophysiology of malignant pleural mesothelioma","volume":"4","author":"Jean","year":"2015","journal-title":"Lung Cancer Management"},{"issue":"12","key":"10.1016\/j.thorsurg.2020.08.005_bib51","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.thorsurg.2020.08.005_bib52","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.thorsurg.2020.08.005_bib53","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.08.599","article-title":"Novel germline mutations in DNA damage repair in patients with malignant pleural mesotheliomas","author":"Guo","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.thorsurg.2020.08.005_bib55","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.thorsurg.2020.08.005_bib56","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.thorsurg.2020.08.005_bib57","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/gcc.22381","article-title":"Different prognostic roles of tumor suppressor gene BAP1 in cancer: a systematic review with meta-analysis","volume":"55","author":"Luchini","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J\u00a0Transl Med"},{"issue":"12","key":"10.1016\/j.thorsurg.2020.08.005_bib59","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib60","doi-asserted-by":"crossref","first-page":"1310478","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?","volume":"2017","author":"Pulford","year":"2017","journal-title":"Dis Markers"},{"issue":"8","key":"10.1016\/j.thorsurg.2020.08.005_bib61","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A\u00a0novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.005_bib62","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1378\/chest.08-2665","article-title":"Malignant pleural mesothelioma: an update on biomarkers and treatment","volume":"136","author":"Ray","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2018.07.041","article-title":"Highlights of the 14th International Mesothelioma Interest Group meeting: pathologic separation of benign from malignant mesothelial proliferations and histologic\/molecular analysis of malignant mesothelioma subtypes","volume":"124","author":"Churg","year":"2018","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.thorsurg.2020.08.005_bib64","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the International Mesothelioma Panel from the MESOPATH reference center","volume":"13","author":"Galateau Salle","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib65","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1126\/science.aan2507","article-title":"A\u00a0pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.thorsurg.2020.08.005_bib66","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.lungcan.2005.03.018","article-title":"Transcriptional profiling of mesothelioma using microarrays","volume":"49","author":"Gordon","year":"2005","journal-title":"Lung Cancer"},{"issue":"2\u20133","key":"10.1016\/j.thorsurg.2020.08.005_bib67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0014-5793(00)01913-X","article-title":"Differential gene expression in mesothelioma","volume":"480","author":"Rihn","year":"2000","journal-title":"FEBS Lett"},{"issue":"8","key":"10.1016\/j.thorsurg.2020.08.005_bib68","first-page":"3080","article-title":"Gene expression profiling of malignant mesothelioma","volume":"9","author":"Singhal","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.005_bib69","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-0607-3","article-title":"Gene expression profiles predict survival and progression of pleural mesothelioma","volume":"10","author":"Pass","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.thorsurg.2020.08.005_bib70","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -a miRNA microarray analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.thorsurg.2020.08.005_bib71","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.mrrev.2011.12.003","article-title":"A\u00a0review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma","volume":"750","author":"Melaiu","year":"2012","journal-title":"Mutat Res"},{"issue":"6","key":"10.1016\/j.thorsurg.2020.08.005_bib72","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.thorsurg.2020.08.005_bib73","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/annonc\/mdu127","article-title":"Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications","volume":"25","author":"Suraokar","year":"2014","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.thorsurg.2020.08.005_bib74","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reynies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib75","series-title":"Asbestos and mesothelioma","first-page":"197","article-title":"Gene signature of malignant pleural mesothelioma","author":"De Rienzo","year":"2017"},{"issue":"22","key":"10.1016\/j.thorsurg.2020.08.005_bib76","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1093\/bioinformatics\/btp543","article-title":"Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis","volume":"25","author":"Shen","year":"2009","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.thorsurg.2020.08.005_bib77","doi-asserted-by":"crossref","first-page":"i237","DOI":"10.1093\/bioinformatics\/btq182","article-title":"Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM","volume":"26","author":"Vaske","year":"2010","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.thorsurg.2020.08.005_bib78","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.thorsurg.2020.08.005_bib79","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib80","series-title":"Analysis-ready standardized TCGA data from Broad GDAC Firehose stddata__2015_06_01run","author":"Center BITGDA","year":"2015"},{"issue":"8","key":"10.1016\/j.thorsurg.2020.08.005_bib81","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/jnci\/95.8.598","article-title":"Using gene expression ratios to predict outcome among patients with mesothelioma","volume":"95","author":"Gordon","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.thorsurg.2020.08.005_bib82","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-04-2181","article-title":"Validation of genomics-based prognostic tests in malignant pleural mesothelioma","volume":"11","author":"Gordon","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.thorsurg.2020.08.005_bib83","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jnci\/djp061","article-title":"Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma","volume":"101","author":"Gordon","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.thorsurg.2020.08.005_bib84","first-page":"4963","article-title":"Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma","volume":"62","author":"Gordon","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.thorsurg.2020.08.005_bib85","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jmoldx.2016.07.011","article-title":"Validation of a gene expression test for mesothelioma prognosis in formalin-fixed paraffin-embedded tissues","volume":"19","author":"De Rienzo","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"issue":"2","key":"10.1016\/j.thorsurg.2020.08.005_bib86","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.18632\/oncotarget.13174","article-title":"Malignant pleural mesothelioma and mesothelial hyperplasia: a new molecular tool for the differential diagnosis","volume":"8","author":"Bruno","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2020.08.005_bib87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2018.10.015","article-title":"Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma","volume":"126","author":"Tranchant","year":"2018","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.thorsurg.2020.08.005_bib88","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14712598.2019.1606209","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"Nowak","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.thorsurg.2020.08.005_bib89","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.thorsurg.2020.08.005_bib90","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.thorsurg.2020.08.005_bib91","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00262-016-1844-3","article-title":"CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor","volume":"65","author":"Roncella","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.thorsurg.2020.08.005_bib92","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Thoracic Surgery Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412720300670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412720300670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:33:18Z","timestamp":1761546798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547412720300670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1547412720300670"],"URL":"https:\/\/doi.org\/10.1016\/j.thorsurg.2020.08.005","relation":{},"ISSN":["1547-4127"],"issn-type":[{"value":"1547-4127","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Molecular Basis of Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Thoracic Surgery Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thorsurg.2020.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}